Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Primary Care Portfolio Total [legacy] by Year
Primary Care Portfolio Total [legacy] — Worldwide reported YoY (%) (%)
Pfizer Primary Care Portfolio Total [legacy]: -11.0% in FY2025, down 9.0 pts from a year earlier.
Latest, FY2025
-11.0%
Period ended Dec 31, 2025
Change on a year earlier
-9.0 pts
-2.0% in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Primary Care | $ | 26,820 | $ | 30,135 | (11%) | (12%) | $ | 15,898 | $ | 18,783 | (15%) | $ | 10,921 | $ | 11,352 | (4%) | (5%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Primary Care Portfolio Total [legacy] — Worldwide reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -11.0% | -9.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -2.0% | +59.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | -61.0% | -95.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 34.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
Cite this data
StockData. (2026). Pfizer Primary Care Portfolio Total [legacy] (%), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/port-leg-pc-yoy
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.